Parabilis Medicines, Inc.
PBLS
$28.80
$2.449.26%
NASDAQ
| 03/31/2026 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 83.75% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 21.10% | ||||
| Operating Income | -21.10% | ||||
| Income Before Tax | -18.24% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -18.24% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -18.24% | ||||
| EBIT | -21.10% | ||||
| EBITDA | -21.59% | ||||
| EPS Basic | -45.01% | ||||
| Normalized Basic EPS | -16.37% | ||||
| EPS Diluted | -45.01% | ||||
| Normalized Diluted EPS | -16.37% | ||||
| Average Basic Shares Outstanding | 1.61% | ||||
| Average Diluted Shares Outstanding | 1.61% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||